52718-95-3

Usage

Uses

Used in Organic Synthesis:
2-Bromo-3-pyridinecarboxylic acid methyl ester is utilized as a key intermediate in organic synthesis for the creation of a wide range of chemical products. Its unique structure and reactivity allow for the development of new compounds with specific properties.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2-Bromo-3-pyridinecarboxylic acid methyl ester is employed as a building block for the synthesis of various pharmaceuticals. Its versatility in chemical reactions enables the production of new drug candidates with potential therapeutic applications.
Used in Agrochemical Development:
Similarly, in the agrochemical sector, 2-Bromo-3-pyridinecarboxylic acid methyl ester is used as a precursor in the synthesis of agrochemicals, contributing to the development of new pesticides and other agricultural products to improve crop protection and yield.
Safety Considerations:
It is important to handle 2-Bromo-3-pyridinecarboxylic acid methyl ester with care due to its irritant properties. It can cause irritation to the skin, eyes, and respiratory system, necessitating proper safety measures during its use in laboratories and industrial settings.

InChI:InChI=1/C7H6BrNO2/c1-11-7(10)5-3-2-4-9-6(5)8/h2-4H,1H3

Upstream product

• 35905-85-2 2-bromonicotinic acid 
• 1972-28-7 diethylazodicarboxylate 
• 13070-22-9 3-(N,N-diethylamino)propenal 
• 105-34-0 methyl 2-cyanoacetate 
• 67-56-1 methanol 
• 654084-12-5 2-bromonicotinoyl chloride 
• 128071-75-0 2-bromopyridine-3-carboxaldehyde 
• 109-04-6 2-bromo-pyridine 
• 124-38-9 carbon dioxide 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 100921-66-2 bromo-2 butyl-3 pyridine 
• 3430-17-9 2-bromo-3-picoline 
• 186581-53-3 diazomethane 

Downstream Products

• 218138-60-4 4-(2-t-Butylaminosulfonyl-phenyl)-phenyl 2-(3-cyanophenyl)-pyridine-3-carboxamide 
• 59361-45-4 methyl 2-((3-(trifluoromethyl)phenyl)amino)nicotinate 
• 1005161-86-3 methyl 2-[(4-methoxyphenyl)ethynyl]nicotinate 
• 1187317-85-6 N₂,N₂-dimethyl-N-[4-(1-oxo-1,2,3,4-tetrahydroazepino[3,4,5-hi]indolizin-5-yl)phenyl]glycinamide 
• 1187318-07-5 5-(4-nitrophenyl)-3,4-dihydroazepino[3,4,5-hi]indolizin-1(2H)-one 
• 1187318-84-8 5-(4-aminophenyl)-3,4-dihydroazepino[3,4,5-hi]indolizin-1(2H)-one 

Relevant academic research and scientific papers

Synthesis and properties of novel N,C,N terdentate skeleton based on 1,3-di(pyridin-2-yl)benzene moiety—new tricks for old dogs

Utilization of intermolecular Friedel–Crafts and intramolecular condensation reaction, novel 1,3-di(pyridine-2-yl)benzene(N,C,N terdentate) skeleton with electro-withdrawing group in 6' position of pyridyl and a cyclization between 6' position of pyridyl and 6 position of benzyl ring were firstly designed and synthesized. The structures of these novel N,C,N terdentate were confirmed by NMR, MS and X-ray single crystalanalyses. The photophysical properties of these compounds were briefly explored.

1,3-bis(2-pyridyl)benzene receptor unit and indacenodipyridine diketone organic semiconductor material and application of organic semiconductor material

The invention discloses a 1,3-bis(2-pyridyl)benzene receptor unit and an indacenodipyridine diketone organic semiconductor material and application of the organic semiconductor material. 1,3-bis(2-pyridyl)benzene is taken as a basic skeleton, an electron

A ultrasonic process for synthesizing 2 - halogenated nicotinate and intermediates thereof

The invention discloses a method for synthesizing 2-halogenated ester nicotinate and a 2-halogenated ester nicotinate intermediate according to an ultrasonic method. The method comprises the following steps: adding substituent amino acrolein, a catalyst and cyanacetic ester into a reactor for a reaction under ultrasonic radiation; tracing the reaction till substituent amino acrolein is disappeared, thereby obtaining a reaction solution I containing the 2-halogenated ester nicotinate intermediate; then, adding halogen hydride into the reaction solution I for another reaction to obtain a reaction solution II; tracing and monitoring the reaction till completion; adding a lye into the reaction solution II to adjust the pH value of the reaction solution II to be 5-6; carrying out standing stratification to obtain a water layer and an organic layer; conducting extraction on the water layer by utilizing an organic solvent, and then combining the extraction solution with the organic layer; carrying out refining to obtain 2-halogenated ester nicotinate. Through the adoption of the method, an organic synthesis reaction can be effectively facilitated, the reaction speed and yield can be improved, and the environmental protection can be promoted; the reaction time is short and the operation is simple, that is, the organic synthesis reaction can be finished within 2 hours in general; the product yield and quality are high; specifically, the product yield can reach 90% or higher, and exceed that achieved according to the conventional solvent heating reflux method.

A microwave synthesis 2 - halogenated nicotinate and intermediates thereof

The invention discloses a method for synthesizing 2-halogenated nicotinic acid ester and intermediates thereof through microwave method. The method comprises the following steps: adding substitute amino acrolein, a catalyst and cyan-acetic ester into a reactor, carrying out reaction under microwave radiation, and tracking the reaction till substitute amino acrolein disappears to prepare and obtain reaction liquid of the intermediates of 2-halogenated nicotinic acid ester; adding hydrogen halide into the reaction liquid, continuously carrying out reaction, and tracking and monitoring the reaction till the reaction is complete; adding alkali liquor into the reaction liquid to adjust the pH value to 5-6; carrying out standing delamination to obtain an aqueous layer and an organic layer; extracting the aqueous layer with an organic solvent, combining the extracted aqueous layer with the organic layer, and carrying out refinement to prepare and obtain 2-halogenated nicotinic acid ester. The synthesis method of 2-halogenated nicotinic acid ester related to the invention has the advantages of beingenvironment-friendly, short in reaction time, simple to operate, high in product yield and good in quality.

Synthesis of 9,9′-Spirobifluorenes and 4,5-Diaza-9,9′-spirobifluorenes and Their Application as Affinity Materials for Quartz Crystal Microbalances

Two different classes of aza analogues of 9,9′-spirobifluorenes have been synthesized. These were obtained by either furnishing the spirobifluorene with additional pyridyl moieties or by installing the aza function directly into the spirobifluorene core. These structurally rigid compounds were then evaluated as affinity materials for quartz crystal microbalances and proved to be highly potent for the detection of volatile organic compounds.

Method using hydrothermal method to synthesize 2-halogeneated nicotinate and 2-halogeneated nicotinic acid

The invention discloses a method using a hydrothermal method to synthesize 2-halogeneated nicotinate and 2-halogeneated nicotinic acid and relates to the field of chemical synthesizing. The method uses substituted amino acrolein, catalyst, catalyst assistant, water and cyanoacetate as raw materials to synthesize the 2-halogeneated nicotinate and the 2-halogeneated nicotinic acid through the hydrothermal method. Compared with the prior art, the method is environmentally friendly, easy in separation, high in product yield, good in product quality, capable of achieving large-scale industrial production favorably, and the like.

HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF

Described herein are compounds, including pharmaceutically acceptable salts thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, prevent or diagnose blood-based diseases, disorders or conditions.

Scope of Successive C-H Functionalizations of the Methyl Group in 3-Picolines: Intramolecular Carbonylation of Arenes to the Metal-Free Synthesis of 4-Azafluorenones

A transition-metal-free, t-BuOOH mediated intramolecular carbonylation of arenes in 2-aryl-3-picolines via oxidative C-H functionalizations of the methyl group has been developed, providing an expedient synthesis of 4-azafluorenones. Distinct from the current literature wherein methylarenes have been used as acylating agents, 2-aryl-3-picolines in this study are transformed into aldehydes, which give 4-azafluorenones upon rapid intramolecular acylation. The study demonstrates the first example of intramolecular carbonylation of arenes utilizing a methyl group as latent carbonyl functionality.

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[ c ][2,6]naphthyridine-8- carboxylic Acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the Treatment of Cancer

Herein we chronicle the discovery of CX-4945 (25n), a first-in-class, orally bioavailable ATP-competitive inhibitor of protein kinase CK2 in clinical trials for cancer. CK2 has long been considered a prime cancer drug target because of the roles of deregulated and overexpressed CK2 in cancer-promoting prosurvival and antiapoptotic pathways. These biological properties as well as the suitability of CK2s small ATP binding site for the design of selective inhibitors, led us to fashion novel therapeutic agents for cancer. The optimization leading to 25n (Ki = 0.38 nM) was guided by molecular modeling, suggesting a strong binding of 25n resulting from a combination of hydrophobic interactions, an ionic bridge with Lys68, and hydrogen bonding with the hinge region. 25n was found to be highly selective, orally bioavailable across species (20-51%) and efficacious in xenograft models. The discovery of 25n will allow the therapeutic targeting of CK2 in humans for the first time.

1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS

The invention relates to compounds of formula I: where X, HAr, a, and R1 through R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.